StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly zepbound — U.S. revenue ($M) ($M)

Form 10-Q / 10-K Note 2 & MD&A

QuarterlyAnnual
Latest, Q2 2026
4,873
Period ended Jun 30, 2026
Change on a year earlier
+44.2%
3,380 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZepbound — U.S. revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20264,873+44.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 20264,134+79.3%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 20254,230+121.8%Form 10-K (filed 2026-02-12) ↗
Q3 2025Sep 30, 20253,568+183.7%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 20253,380+171.9%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20252,305+345.5%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 20241,908+983.9%Form 10-K (filed 2026-02-12) ↗
Q3 2024Sep 30, 20241,258–Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 20241,243–Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024517–Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023176–Form 10-K (filed 2026-02-12) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-04-30) ↗

Cite this data

StockData. (2026). Eli Lilly Zepbound — U.S. revenue ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_zepbound_us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.